TF
AXSM icon

Trek Financial’s Axsome Therapeutics AXSM Stock Holding History

Trek Financial’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-29,544
Closed -$3.45M – 420
2025
Q1 		$3.45M Buy
+29,544
New +$3.37M 0.25% 96

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Trek Financial's AXSM Position: Q2 2025 in Review

Trek Financial sold out of Axsome Therapeutics (AXSM) in Q2 2025, closing a stake of 29,544 shares — an estimated $3.45M sold.

Trek Financial first reported a position in AXSM in Q1 2025 and held it in 1 quarter. The position peaked at $3.45M in Q1 2025. 348 funds tracked by Wall St. Rank hold AXSM as of Q2 2025.

  • Trek Financial reported no remaining Axsome Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Trek Financial sold 29,544 Axsome Therapeutics shares in Q2 2025, an estimated $3.45M.
  • Trek Financial first reported a position in Axsome Therapeutics in Q1 2025 and held it in 1 quarter.
  • Trek Financial's Axsome Therapeutics position peaked at $3.45M in Q1 2025.
  • 348 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2025.

Based on Trek Financial's 13F filing for Q2 2025, filed 13 Aug 2025.